Published in Tuberculosis Week, September 6th, 2004
According to recent research published in the journal Vaccine, "The use of protein or DNA in vaccination process, rather than living or attenuated microorganism, aims at the increase of vaccine safety. However, in these cases, the use of an adjuvant frequently is required to improve immunogenicity. In this study, we show the importance of adjuvant in a vaccine formulation."
"Vaccines for tuberculosis provide an instructive example, based on the mycobacterial 65-kDa heat shock protein (hsp65)," said Karla M. Lima and colleagues at the University of Sao Paulo. "The same antigen can elicit...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Tuberculosis Week